Literature DB >> 26645989

Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers.

Detlef Kindgen-Milles1, Marlies Ostermann2, Torsten Slowinski3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26645989      PMCID: PMC4673790          DOI: 10.1186/s13054-015-1143-y

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
Schwarzer et al. [1] showed discrepant postfilter ionized calcium concentrations [iCa] when using different blood gas analyzers (BGAs) and called for a change of the Fresenius regional citrate anticoagulation (RCA) protocol to ensure patient safety. Of note, precision of the BGAs was not tested. In our opinion, the key message of their study is that commercially available BGAs are not accurate when measuring [iCa] outside the reference range and therefore clinicians should avoid using multiple BGAs to guide RCA in individual patients. However, there is no indication to change a RCA protocol which has been proven safe and effective in >10 studies including >2000 patients from different countries regardless of the BGA used [2-5]. Schwarzer et al. also raise concern about the potential risk of life-threatening citrate intoxication. Whether raised citrate levels are toxic or merely indicative of impaired cellular metabolism remains unclear, but excess citrate can cause metabolic alkalosis. The Fresenius RCA protocol and the technical specifications of the multifiltrate machine both include safety mechanisms to detect potential citrate accumulation early. The risk of citrate toxicity is low (<3 %), even in high-risk patients with liver failure [3, 5]. Given the proven advantages of RCA and the Kidney Disease Improving Global Outcomes (KDIGO) recommendation to use citrate as the first-line anticoagulant during continuous renal replacement therapy, the accuracy of commercially available BGA devices should be improved. In our opinion, there is no need to change a safe and effective protocol.
  5 in total

1.  Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation.

Authors:  Dmytro Khadzhynov; Christin Schelter; Ina Lieker; Alice Mika; Oliver Staeck; Hans-H Neumayer; Harm Peters; Torsten Slowinski
Journal:  J Crit Care       Date:  2013-11-11       Impact factor: 3.425

2.  A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status.

Authors:  Stanislao Morgera; Michael Schneider; Torsten Slowinski; Ortrud Vargas-Hein; Heidrun Zuckermann-Becker; Harm Peters; Detlef Kindgen-Milles; Hans-Hellmut Neumayer
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

3.  Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.

Authors:  Robert Kalb; Rainer Kram; Stanislao Morgera; Torsten Slowinski; Detlef Kindgen-Milles
Journal:  Ther Apher Dial       Date:  2012-08-29       Impact factor: 1.762

4.  Discrepant post filter ionized calcium concentrations by common blood gas analyzers in CRRT using regional citrate anticoagulation.

Authors:  Patrik Schwarzer; Sven-Olaf Kuhn; Sylvia Stracke; Matthias Gründling; Stephan Knigge; Sixten Selleng; Maximilian Helm; Sigrun Friesecke; Peter Abel; Anders Kallner; Matthias Nauck; Astrid Petersmann
Journal:  Crit Care       Date:  2015-09-08       Impact factor: 9.097

5.  Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.

Authors:  Torsten Slowinski; Stanislao Morgera; Michael Joannidis; Thomas Henneberg; Reto Stocker; Elin Helset; Kirsti Andersson; Markus Wehner; Justyna Kozik-Jaromin; Sarah Brett; Julia Hasslacher; John F Stover; Harm Peters; Hans-H Neumayer; Detlef Kindgen-Milles
Journal:  Crit Care       Date:  2015-09-29       Impact factor: 9.097

  5 in total
  1 in total

1.  Electrolyte monitoring during regional citrate anticoagulation in continuous renal replacement therapy.

Authors:  C Warnar; E Faber; P A Katinakis; T Schermer; P E Spronk
Journal:  J Clin Monit Comput       Date:  2021-05-15       Impact factor: 1.977

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.